All in all, our and others’ studies provide clear evidence for the role of FOXA1 in breast cancer and prostate cancer progression and treatment response, suggesting that the targeting of FOXA1 may be useful, in combination with standard therapy, in treatment. The gene discussed is FOXA1; the disease is Familial prostate cancer.